Press Releases

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.

Date	Title and Summary	Additional Formats
Toggle SummaryOct282015	Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions Proprietary Pluripotent Cell Platform Has Broad Applicability for Development of Off-the-Shelf Cancer Immunotherapies Read All »	View HTML Fate Therapeutics Strengthens Intellectual Property Position With New U.S. Patent Covering Induced Pluripotent Cell Compositions 20.8 KB
Toggle SummaryOct122015	Fate Therapeutics Announces Leadership Transition Scott Wolchko , a Fate Founder, to Succeed Christian Weyer as President and CEO Effective December 1, 2015 Additional Leadership Changes Enhance Fate Executive Team SAN DIEGO , Oct. 12, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the Read All »	View HTML Fate Therapeutics Announces Leadership Transition 22.8 KB
Toggle SummarySep022015	Fate Therapeutics to Present at September Investor Conferences SAN DIEGO, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced that Christian Weyer, M.D., M.A.S., President Read All »	View HTML Fate Therapeutics to Present at September Investor Conferences 10.6 KB
Toggle SummaryAug062015	Fate Therapeutics to Present at Upcoming Investor Conferences SAN DIEGO, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life-threatening diseases, today announced that management will be presenting at two Read All »	View HTML Fate Therapeutics to Present at Upcoming Investor Conferences 10.6 KB
Toggle SummaryAug052015	Fate Therapeutics Reports Second Quarter 2015 Financial Results Interim Data From PROHEMA® PUMA Study Show Reduction in Severe Infections Across Multiple Pathogen Types First Pediatric Subject Treated in PROHEMA® PROVIDE Study of CNS Cellular Replacement Strategic Research Collaboration Formed With Juno Therapeutics to Identify Small Molecule Read All »	View HTML Fate Therapeutics Reports Second Quarter 2015 Financial Results 38.5 KB
Toggle SummaryJul292015	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5, 2015 SAN DIEGO, July 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2015 Financial Results on August 5, 2015 10.7 KB
Toggle SummaryJul152015	Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, announced today that it has named Dr. Read All »	View HTML Fate Therapeutics Appoints Dr. Stewart Abbot as Vice President, Translational Research 15.1 KB
Toggle SummaryJul142015	Fate Therapeutics and Regents of the University of Minnesota Enter Into Research Collaboration for Translation of Natural Killer Cell Cancer Immunotherapies "Adaptive" Natural Killer Cell Therapeutics to be Advanced as Antibody-Mediated Cancer Therapy Genetically-Engineered Induced Pluripotent Stem Cell-derived Natural Killer Cells to be Developed as Off-the-Shelf Targeted Immunotherapy Fate Therapeutics Holds an Exclusive Option to Secure All Patent Read All »	View HTML Fate Therapeutics and Regents of the University of Minnesota Enter Into Research Collaboration for Translation of Natural Killer Cell Cancer Immunotherapies 23.9 KB
Toggle SummaryJun052015	Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases Proof-of-Concept Data in Well-Established Model of Type 1 Diabetes Presented Today at the 75th Scientific Sessions of the American Diabetes Association Read All »	View HTML Fate Therapeutics Enters Into Sponsored Research Agreement With Boston Children's Hospital to Develop Immunoregulatory Cell Therapy for Treatment of Autoimmune Diseases 23.7 KB
Toggle SummaryMay272015	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO , May 27, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the closing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 147.1 KB
Toggle SummaryMay202015	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , May 20, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the pricing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Pricing of Public Offering of Common Stock 148.1 KB
Toggle SummaryMay182015	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO , May 18, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that it has commenced an underwritten public Read All »	View HTML Fate Therapeutics Announces Proposed Public Offering of Common Stock 20.8 KB
Toggle SummaryMay072015	Fate Therapeutics Reports First Quarter 2015 Financial Results Strategic Research Collaboration Established with Juno Therapeutics to Apply Small Molecule Modulators for Programming CAR and TCR Immunotherapies Additional Data from Ongoing Phase 2 PUMA Study of PROHEMA® Continue to Demonstrate Acceleration of, and Increased Incidence of Early, Neutrophil Read All »	View HTML Fate Therapeutics Reports First Quarter 2015 Financial Results 30.9 KB
Toggle SummaryMay062015	Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies Alliance Utilizes Fate's Hematopoietic Cell Programming Platform to Identify Small Molecule Modulators for Juno's Leading Genetically-Engineered T Cell Immunotherapies Read All »	View HTML Juno Therapeutics and Fate Therapeutics Announce Strategic Research Collaboration to Improve the Therapeutic Profile of Engineered T Cell Immunotherapies 27.1 KB
Toggle SummaryMay042015	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 SAN DIEGO, May 4, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that the Company will host a conference call and live Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2015 Financial Results on May 7, 2015 10.8 KB